The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S.

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in ge ...

A single gene therapy injection has shown the ability to restore hearing in patients with a specific genetic mutation, with ...

MeiraGTx (MGTX) stock jumps as the company plans to disclose long-term data from a Phase 1 trial for its gene therapy ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles is proud to announce the launch of its new line of Alkali-Tolerant AAV Affinity Agarose Resins. Specifically ...

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...

If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children ...

The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...

For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in.